Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.37 |
| ▸ | UGT1A4 | P22310 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | FDPS | P14324 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10721461 | 0.83 | EGLN3 (0.47) | EGLN3ALDH1A1MAPTSMN1; SMN2CYP19A1 | |
| SCHEMBL14723248 | 0.76 | EGLN3 (0.44) | EGLN3ALDH1A1MAPTSMN1; SMN2CYP19A1 | |
| SCHEMBL13017117 | 0.76 | EGLN3 (0.44) | EGLN3ALDH1A1MAPTSMN1; SMN2CYP3A4 | |
| SCHEMBL20142982 | 0.75 | EGLN3 (0.47) | EGLN3ALDH1A1MAPTSMN1; SMN2CYP19A1 | |
| SCHEMBL13017154 | 0.73 | EGLN3 (0.42) | EGLN3ALDH1A1MAPTSMN1; SMN2CYP3A4 | |
| SCHEMBL14003700 | 0.73 | MEN1 (0.42) | EGLN3ALDH1A1MAPTSMN1; SMN2CYP3A4 | |
| SCHEMBL855088 | 0.72 | — | — | |
| SCHEMBL45842 | 0.72 | — | — | |
| SCHEMBL17159811 | 0.71 | EGLN3 (0.56) | EGLN3ALDH1A1MAPTSMN1; SMN2CYP19A1 | |
| SCHEMBL10338984 | 0.71 | EGLN3 (0.56) | EGLN3ALDH1A1MAPTSMN1; SMN2CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295112-A1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2023-09-21 | — | — | US | disclosed |
| US-20230295112-A1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2023-09-21 | — | — | US | disclosed |
| US-20220048885-A1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2022-02-17 | — | — | US | disclosed |
| US-11078182-B2 | Heteroaromatic compounds as Vanin inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-08-03 | — | — | US | disclosed |
| US-20200172508-A1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-06-04 | — | — | US | disclosed |
| EP-1720546-B1 | NOVEL, SUSTAINED-ACTION BETA-2-AGONISTS AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2010-09-01 | — | — | EP | disclosed |
| EP-1720546-B1 | NOVEL, SUSTAINED-ACTION BETA-2-AGONISTS AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2010-09-01 | — | — | EP | disclosed |
| US-7511067-B2 | 3-hydroxymethyl-4-hydroxy-phenyl-derivatives for the treatment of respiratory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-03-31 | — | — | US | disclosed |
| US-7405232-B2 | Long acting beta-2 agonists and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-29 | — | — | US | disclosed |
| US-7405232-B2 | Long acting beta-2 agonists and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-29 | — | — | US | disclosed |
| US-7405232-B2 | Long acting beta-2 agonists and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-29 | — | — | US | disclosed |
| US-20080132556-A1 | 3-HYDROXYMETHYL-4HYDROXY-PHENYL- DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES | BOUYSSOU THIERRY | 2008-06-05 | — | — | US | disclosed |
| EP-1720546-A1 | NOVEL, SUSTAINED-ACTION BETA-2-AGONISTS AND THEIR USE AS MEDICAMENTS | Boehringer Ingelheim International GmbH (DE) | 2006-11-15 | — | — | EP | disclosed |
| EP-1706389-A1 | 3-HYDROXYMETHYL-4-HYDROXY-PHENYL DERIVATIVES FOR THE TREATMENT OF RESPIRATORY ILLNESSES | Boehringer Ingelheim International GmbH (DE) | 2006-10-04 | — | — | EP | disclosed |
| US-20050234112-A1 | 3-Hydroxymethyl-4-hydroxy-phenyl-derivatives for the treatment of respiratory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-20 | — | — | US | disclosed |
| US-20050197374-A1 | New long acting beta-2 agonists and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-09-08 | — | — | US | disclosed |
| WO-2005077361-A1 | NOVEL, SUSTAINED-ACTION BETA-2-AGONISTS AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-08-25 | — | — | WO | disclosed |
| WO-2005066140-A1 | 3-HYDROXYMETHYL-4-HYDROXY-PHENYL DERIVATIVES FOR THE TREATMENT OF RESPIRATORY ILLNESSES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197374-A1 | New long acting beta-2 agonists and their use as medicaments | ADRB2, ADRA2A, ADRA2C | EGLN3 3094/4885ALDH1A1 1938/4885MAPT 3550/4885 |
| US-20220048885-A1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | VHL, FANCI, PAH | EGLN3 423/4885ALDH1A1 543/4885MAPT 3447/4885 |
| US-20200172508-A1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | VHL, FANCI, PAH | EGLN3 423/4885ALDH1A1 543/4885MAPT 3447/4885 |
| US-11078182-B2 | Heteroaromatic compounds as Vanin inhibitors | VHL, FANCI, PAH | EGLN3 423/4885ALDH1A1 543/4885MAPT 3447/4885 |
| US-20050234112-A1 | 3-Hydroxymethyl-4-hydroxy-phenyl-derivatives for the treatment of respiratory diseases | PAH, CYP11B1, CYP11B2 | EGLN3 9/4885ALDH1A1 272/4885MAPT 4330/4885 |
| US-20230295112-A1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | VHL, FANCI, PAH | EGLN3 423/4885ALDH1A1 543/4885MAPT 3447/4885 |
| US-20080132556-A1 | 3-HYDROXYMETHYL-4HYDROXY-PHENYL- DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES | PAH, CYP1A1, CYP11B1 | EGLN3 11/4885ALDH1A1 281/4885MAPT 4138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.